Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -1.2 million
▼ 225% vs 2024
Profit
Caution€ -1.9 million
▲ 60% vs 2024
Debts
Low€ 85,956
▼ 91% vs 2024
ExeVir Bio from Gent, company number BE0750495334, closed financial year 2025 with a result of € -1.9 million after tax. For that financial year ExeVir Bio recorded a gross margin of € -1.2 million and equity of € 3.7 million. Compared with financial year 2024, the result moved from € -4.8 million to € -1.9 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
What happened at ExeVir Bio?
What happened at ExeVir Bio in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Stefaan HEYLEN stepped down as director. NBB
- Erika WHITTAKER stepped down as director. NBB
- Halina NOVAK stepped down as director. NBB
- Jérôme VAN BIERVLIET stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.9 million. Source: NBB ↗
- Stefaan HEYLEN became a director. NBB
- Jeanne BOLGER stepped down as director. NBB
- SPARAXIS NV stepped down as director. NBB
In short
From € 27.3 million loss in 2021 to € 1.9 million loss in 2025.
On average € 103,200 of value added per employee in 2024.
A new publication or filing at ExeVir Bio? We notify you, reason included.
Follow ExeVir BioNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Stefaan HEYLEN
Director
since 2026 · until 2032
Jeanne BOLGER
Director
since 2022 · until 2026
Director · represented by Caroline Thielen
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more
since 2020 · until 2026
Kenneth BONHEURE
Director
since 2024 · until 2026
Michael GARRETT
Managing director
since 2024 · until 2026
Erika WHITTAKER
Director
since 2026 · until 2032
Halina NOVAK
Director
since 2026 · until 2032
Jérôme VAN BIERVLIET
Director
since 2026 · until 2032
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 94
9052 Gent
Boulevard de Patience et Beaujonc 3 box 14
4000 Liège
Active since 1 January 2022
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
BioLyo Technologies
€ 1 million gross margin · 2024
Zomagen Biosciences Belgium
€ 1.2 million gross margin · 2025
AnimAb
€ 28,596 gross margin · 2025
Protealis
€ 1.1 million gross margin · 2025
YAKULT HONSHA EUROPEAN RESEARCH CENTER FOR MICROBIOLOGY
+1 more
Details
- Company number
- 0750.495.334
- VAT number
- BE 0750.495.334
- Registered office
- Technologiepark-Zwijnaarde 94, 9052 Gent
- Names & denominations
- ExeVir Bio · ExeVir
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 July 2020
- Peppol
- Active · Active since 20 Nov 2020
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied